Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-cell RNA profiling of oligodendroglial lineage cells derived from iPSCs carrying Parkinson's disease-relevant LRRK2-G2019S mutation.

iScience·2026
Same author

Higher disease reactivation risk in women after fingolimod withdrawal.

Acta neuropathologica communications·2026
Same author

Brain Immune Cell Composition in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy After Natalizumab: An Immunohistochemical Cohort Study.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

New insights in multiple sclerosis pathology.

Current opinion in neurology·2026
Same author

Age and Maturation Stage Linked Consequences of Fibrinogen on Human Oligodendroglia.

Journal of neuroscience research·2026
Same author

Enhanced myelination potential of human mature oligodendrocytes by TNF and IFNG combination.

Journal of neuroinflammation·2026

Related Experiment Video

Updated: May 8, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Limited TCF7L2 expression in MS lesions.

Alexander Lürbke1, Karin Hagemeier, Qiao-Ling Cui

  • 1Institute of Neuropathology, University Hospital Münster, Münster, Germany.

Plos One
|August 27, 2013
PubMed
Summary
This summary is machine-generated.

TCF7L2 expression in oligodendrocytes is limited to specific differentiation stages during development and remyelination. However, its expression is not exclusive to oligodendrocytes or myelinating conditions in multiple sclerosis.

More Related Videos

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

Related Experiment Videos

Last Updated: May 8, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

Area of Science:

  • Neuroscience
  • Cell Biology
  • Pathology

Background:

  • Multiple sclerosis (MS) is a primary demyelinating disease of the central nervous system (CNS), marked by inflammation, myelin loss, and axonal damage.
  • Limited remyelination in chronic MS is partly due to impaired oligodendroglial precursor cell differentiation.
  • TCF7L2 is an oligodendroglial transcription factor crucial for myelin gene regulation during development and remyelination.

Purpose of the Study:

  • To investigate TCF7L2 as a potential marker for differentiating or myelinating oligodendrocytes.
  • To analyze TCF7L2 expression patterns during developmental myelination and remyelination in human and murine CNS tissues.

Main Methods:

  • Analysis of TCF7L2 expression in human and murine CNS tissue samples.
  • Examination of oligodendroglial differentiation and myelination markers.
  • Investigation of TCF7L2 co-factor interactions, including HDAC2.

Main Results:

  • TCF7L2 expression in oligodendrocytes is temporally restricted to specific periods of developmental myelination in both species.
  • TCF7L2 is reexpressed in oligodendrocytes in a subset of multiple sclerosis patients.
  • TCF7L2 expression was also detected in astrocytes and in non-demyelinating inflammatory diseases, indicating it is not exclusive to oligodendroglial lineage or active remyelination.

Conclusions:

  • TCF7L2 expression in oligodendrocytes is a marker for a specific differentiation stage, not a universal indicator of myelination or remyelination.
  • TCF7L2's presence in astrocytes and non-demyelinating conditions suggests broader roles beyond oligodendroglial function.
  • TCF7L2 is not a specific marker for differentiating or myelinating oligodendrocytes in the context of multiple sclerosis or normal development.